Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma

Lenvatinib was expected to enhance the effect of immune checkpoint inhibitors (ICIs) for unresectable HCC; however, their combination therapy failed to show the synergy in the phase III clinical trial. METHODS: To elucidate lenvatinib-induced molecular modulation, we performed bulk RNA-sequencing an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Tomoharu, Fujiwara, Naoto, Kubota, Naoto, Matsushita, Yuki, Nakatsuka, Takuma, Kurosaki, Shigeyuki, Minami, Tatsuya, Tateishi, Ryosuke, Ichida, Akihiko, Arita, Junichi, Hasegawa, Kiyoshi, Koike, Kazuhiko, Fujishiro, Mitsuhiro, Nakagawa, Hayato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351952/
https://www.ncbi.nlm.nih.gov/pubmed/37471053
http://dx.doi.org/10.1097/HC9.0000000000000209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351952/
https://www.ncbi.nlm.nih.gov/pubmed/37471053
http://dx.doi.org/10.1097/HC9.0000000000000209

Ejemplares similares